Smithfield, RI The Davis Companies (Davis) reached a full-building lease agreement at 100 Technology Way, a 123,000 s/f biomanufacturing facility, with Organogenesis Holdings Inc. (Organogenesis), a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis will expand its biomanufacturing production lines to the site and will utilize its new space in Rhode Island to enhance the capabilities of its current production lines. The expansion highlights the commitment by Organogenesis to conduct its manufacturing operations in New England and continue to invest in the local economy.

“In a competitive manufacturing and life sciences market, our lease agreement with Organogenesis demonstrates Davis’ commitment to providing premier tenant experiences in locations that best allow businesses to innovate and scale,” said Davis’ senior vice president of asset management Jon Needham. “We are thrilled to welcome Organogenesis to the building and to support their growth plans as the company leads in the biomanufacturing sector and enhances Rhode Island’s and greater New England’s innovation ecosystem.”

A multi-year construction project is now underway which will enhance 100 Technology Way’s existing capabilities as a cGMP facility. The building is fed by a significant utility infrastructure which will support Organogenesis’ manufacturing uses.

Situated just off I-295 with access to Cambridge and Boston, 100 Technology Way is situated to support biomanufacturing for New England’s life science community.

Organogenesis was represented by Robert Coughlin and Bobby Jangro of JLL, and Mark Winters and Tyler McGrail of Newmark represented Davis and the property.